Skip to Content

Citrolith (potassium citrate / sodium citrate) Disease Interactions

There are 11 disease interactions with Citrolith (potassium citrate / sodium citrate):

Major

Alkalinizing agents (applies to Citrolith) sodium/water balance

Major Potential Hazard, High plausibility. Applicable conditions: Fluid Retention, Congestive Heart Failure, Hypokalemia, Hypernatremia

Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure. Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.

References

  1. "Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra USA, Westborough, MA.
  2. "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical, Abbott Park, IL.
Major

Laxatives (applies to Citrolith) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
Major

Laxatives (applies to Citrolith) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
  5. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
View all 5 references
Major

Potassium citrate (applies to Citrolith) UTI

Major Potential Hazard, High plausibility. Applicable conditions: Urinary Tract Infection

The use of potassium citrate for management of renal tubular acidosis and renal stones is contraindicated in patients with active urinary tract infection caused by urea-splitting organisms. Its ability to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth.

References

  1. "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.
Major

Potassium salts (applies to Citrolith) dehydration

Major Potential Hazard, High plausibility. Applicable conditions: Diarrhea

Administration of potassium salts in severe dehydration may predispose to renal impairment. Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress). Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.

References

  1. "Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical, Abbott Park, IL.
  3. "Product Information. Kaon (potassium gluconate)." Savage Laboratories, Melville, NY.
  4. "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.
View all 4 references
Major

Potassium salts (applies to Citrolith) familial periodic paralysis

Major Potential Hazard, High plausibility.

Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita. Therapy with potassium preparations should be administered cautiously in patients with these conditions.

References

  1. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
Major

Potassium salts (applies to Citrolith) hyperkalemia

Major Potential Hazard, High plausibility. Applicable conditions: Acidosis, Adrenal Insufficiency, Burns - External, Diabetes Mellitus, Hemolytic Anemia

The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest. Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis). Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.

References

  1. "Product Information. Kaon (potassium gluconate)." Savage Laboratories, Melville, NY.
  2. Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984): 270-1
  3. Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988): 97-8,101-2
  4. Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973): 660-1
  5. "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.
  6. "Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical, Abbott Park, IL.
  7. Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978): 1339
  8. Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982): 546-7
  9. "Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb, Princeton, NJ.
  10. Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40
  11. Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989): 1083-91
  12. "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.
  13. Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976): 2125-6
  14. Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972): 156-68
  15. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  16. Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986): 255-6
  17. Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980): 485-6
  18. Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980): 69-71
  19. Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975): 708-11
View all 19 references
Major

Potassium salts (applies to Citrolith) renal dysfunction

Major Potential Hazard, High plausibility.

The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia. Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest. Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency). Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.

References

  1. "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.
  2. "Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb, Princeton, NJ.
  3. "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.
  4. "Product Information. Kaon (potassium gluconate)." Savage Laboratories, Melville, NY.
  5. "Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical, Abbott Park, IL.
View all 5 references
Major

Potassium salts (oral) (applies to Citrolith) GI irritation

Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction, Peptic Ulcer, Gastrointestinal Hemorrhage, History - Peptic Ulcer, Duodenitis/Gastritis, Gastrointestinal Perforation, Esophageal Disease

The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes. Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact. Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years. Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium. Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.

Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation. Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid. Potassium liquids should be diluted prior to consumption.

References

  1. Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984): 405-11
  2. Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970): 134-9
  3. "Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965): 57-8
  4. Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987): 206-9
  5. Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973): 289-94
  6. McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61
  7. Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983): 261-2
  8. Javett S "Slow k ulcer." S Afr J Surg 13 (1975): 64
  9. Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986): 210-2
  10. Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967): 814-5
  11. McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 581-2
  12. Mason SJ, O'Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981): 115-20
  13. Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40
  14. Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965): 383-5
  15. Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976): 495-6
  16. Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976): 251-2
  17. Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7
  18. Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975): 542
  19. Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994): 1268
  20. Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546
  21. Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974): 143-4
  22. Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965): 1127
  23. "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.
  24. McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5
  25. Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986): 192-4
  26. Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965): 22
  27. Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965): 745-9
  28. Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980): 23-5
  29. Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979): 377-9
  30. Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966): 97-101
  31. Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983): 251-2
  32. Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8
  33. Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2
  34. Hasker W, McCaffrey J "Ulceration of a Meckel's diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972): 261-2
  35. Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970): 518-23
  36. Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990): 420-4
  37. Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991): 1127-33
  38. Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979): 1673-6
  39. Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966): 291-6
  40. Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987): 490
  41. Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985): 453
  42. Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967): 32-50,73-74,76-77
  43. Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206
  44. Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987): 954-7
  45. Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11
  46. Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965): 492-3
  47. Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978): 542-3
  48. Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976): 698-9
  49. Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976): 595-8
  50. Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965): 998-1001
  51. Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn's disease." Dig Dis Sci 31 (1986): 1387-90
  52. Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967): 7-11
  53. Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5
  54. "Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966): 138-41
  55. Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968): 76-80
  56. Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967): 136-8
  57. Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969): p315-8assim
  58. "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.
  59. Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971): 344
  60. Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974): 463-5
  61. "Potassium chloride and bowel ulceration." Br Med J 5475 (1965): 1383-4
  62. Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989): 855-6
  63. Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966): 421-5
  64. Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984): 392-7
  65. Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986): 819-34
  66. Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986): 157-63
  67. Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980): 185-8,190
  68. Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965): 570
  69. Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976): 365
  70. Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965): 1409-12
  71. Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977): 1124-5
  72. "Product Information. Kaon (potassium gluconate)." Savage Laboratories, Melville, NY.
  73. Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987): 788-9
View all 73 references
Moderate

Alkalinizing agents (applies to Citrolith) acid/base balance

Moderate Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction, Renal Dysfunction, Seizures, Alkalosis, Arrhythmias

Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions. Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis. Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release. Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function. Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.

References

  1. "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Tham (tromethamine)." Abbott Pharmaceutical, Abbott Park, IL.
  3. "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.
Moderate

Potassium alkali salts (applies to Citrolith) alkalosis

Moderate Potential Hazard, High plausibility.

Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition. In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride. Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.

References

  1. "Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical, Abbott Park, IL.
  3. Walker WG, Jost LJ "Relative roles of patassium and chloride in correction of hypokalemic hypochloremic alkalosis." Johns Hopkins Med J 120 (1967): 148-54
  4. "Product Information. Kaon (potassium gluconate)." Savage Laboratories, Melville, NY.
View all 4 references

Citrolith (potassium citrate / sodium citrate) drug interactions

There are 250 drug interactions with Citrolith (potassium citrate / sodium citrate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.